1rw8

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /> <applet load="1rw8" size="450" color="white" frame="true" align="right" spinBox="true" caption="1rw8, resolution 2.40&Aring;" /> '''Crystal Structure o...)
Line 1: Line 1:
-
[[Image:1rw8.gif|left|200px]]<br />
+
[[Image:1rw8.gif|left|200px]]<br /><applet load="1rw8" size="350" color="white" frame="true" align="right" spinBox="true"
-
<applet load="1rw8" size="450" color="white" frame="true" align="right" spinBox="true"
+
caption="1rw8, resolution 2.40&Aring;" />
caption="1rw8, resolution 2.40&Aring;" />
'''Crystal Structure of TGF-beta receptor I kinase with ATP site inhibitor'''<br />
'''Crystal Structure of TGF-beta receptor I kinase with ATP site inhibitor'''<br />
==Overview==
==Overview==
-
We have expanded our previously reported series of pyrazole-based, inhibitors of the TGF-beta type I receptor kinase domain (TbetaR-I) to now, include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited, examination of the SAR of this new series in both enzyme and cell based in, vitro assays has revealed selectivity differences with respect to p38 MAP, kinase (p38 MAPK) depending on the nature of the 'warhead' group on the, dihydropyrrolopyrazole ring. As with our original pyrazole series, phenyl, substituents tended to show greater selectivity against p38 MAPK than, those comprised of the quinoline-4-yl moiety. We have also achieved, co-crystallization and X-ray analysis of compounds 3 and 15, two potent, examples of this new series, with the TbetaR-I receptor kinase domain.
+
We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-beta type I receptor kinase domain (TbetaR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, phenyl substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray analysis of compounds 3 and 15, two potent examples of this new series, with the TbetaR-I receptor kinase domain.
==Disease==
==Disease==
Line 11: Line 10:
==About this Structure==
==About this Structure==
-
1RW8 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with 580 as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1RW8 OCA].
+
1RW8 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=580:'>580</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Active as [http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1RW8 OCA].
==Reference==
==Reference==
Line 18: Line 17:
[[Category: Non-specific serine/threonine protein kinase]]
[[Category: Non-specific serine/threonine protein kinase]]
[[Category: Single protein]]
[[Category: Single protein]]
-
[[Category: Sawyer, J.S.]]
+
[[Category: Sawyer, J S.]]
[[Category: Zhang, F.]]
[[Category: Zhang, F.]]
[[Category: 580]]
[[Category: 580]]
Line 24: Line 23:
[[Category: tgf-beta receptor i]]
[[Category: tgf-beta receptor i]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 19:07:30 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:55:11 2008''

Revision as of 12:55, 21 February 2008


1rw8, resolution 2.40Å

Drag the structure with the mouse to rotate

Crystal Structure of TGF-beta receptor I kinase with ATP site inhibitor

Contents

Overview

We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-beta type I receptor kinase domain (TbetaR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both enzyme and cell based in vitro assays has revealed selectivity differences with respect to p38 MAP kinase (p38 MAPK) depending on the nature of the 'warhead' group on the dihydropyrrolopyrazole ring. As with our original pyrazole series, phenyl substituents tended to show greater selectivity against p38 MAPK than those comprised of the quinoline-4-yl moiety. We have also achieved co-crystallization and X-ray analysis of compounds 3 and 15, two potent examples of this new series, with the TbetaR-I receptor kinase domain.

Disease

Known diseases associated with this structure: Aortic aneurysm, familial thoracic 5 OMIM:[190181], Furlong syndrome OMIM:[190181], Loeys-Dietz syndrome OMIM:[190181]

About this Structure

1RW8 is a Single protein structure of sequence from Homo sapiens with as ligand. Active as Non-specific serine/threonine protein kinase, with EC number 2.7.11.1 Full crystallographic information is available from OCA.

Reference

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain., Sawyer JS, Beight DW, Britt KS, Anderson BD, Campbell RM, Goodson T Jr, Herron DK, Li HY, McMillen WT, Mort N, Parsons S, Smith EC, Wagner JR, Yan L, Zhang F, Yingling JM, Bioorg Med Chem Lett. 2004 Jul 5;14(13):3581-4. PMID:15177479

Page seeded by OCA on Thu Feb 21 14:55:11 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools